Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Clinical trial NCT07521657 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07521657
- Sponsor
- University of Alabama at Birmingham
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2030-08-01
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.